Chardan Capital weighs in on Coya Therapeutics, Inc.’s FY2024 earnings. (NASDAQ:COYA)

Coya Therapeutics, Inc. (NASDAQ:COYA – Free Report) – Research analysts at Chardan Capital boosted their FY2024 earnings estimates for shares of Coya Therapeutics in a report issued on Tuesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of ($1.17) per share for the year, up from their prior estimate of ($1.30). Chardan Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.30) per share.

Separately, Rodman & Renshaw initiated coverage on shares of Coya Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $18.00 price objective on the stock.

Read our latest research report on COYA

Coya Therapeutics trading rose 2.2%

Shares of Coya Therapeutics stock opened at $5.12 on Friday. The company’s fifty day simple moving average is $6.57 and two hundred day simple moving average is $7.80. The company has a market cap of $74.84 million, a P/E ratio of -6.02 and a beta of 0.59. Coya Therapeutics has a 12 month low of $3.21 and a 12 month high of $10.69.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new stake in shares of Coya Therapeutics in the second quarter valued at about $101,000. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics in the second quarter valued at about $61,000. Vanguard Group Inc. raised its position in shares of Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the period. Greenlight Capital Inc. boosted its stake in Coya Therapeutics by 172.2% in the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after buying an additional 805,959 shares in the last quarter. Finally, AIGH Capital Management LLC boosted its stake in Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000. after buying an additional 496,183 shares in the last quarter. 39.75% of shares are owned by hedge funds and other institutional investors.

About Coya Therapeutics

(Get a free report)

Coya Therapeutics, Inc, a clinical-stage biotechnology company, is engaged in the development of proprietary medicines to modulate the function of regulatory T cells (Tregs). The company’s pipeline of product candidates is based on therapeutic modalities such as Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapy.

Recommended articles

Get news and reviews for Coya Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Coya Therapeutics and related companies with MarketBeat.com ‘s FREE daily newsletter.